Separately, both CHOP chemo-therapy and the monclonal antibody rituximab are known to have activity in low-grade lymphomas. A trial of the two combined shows synergy in non-Hodgkins lymphoma with high response rates and prolonged decline in tumor size.
Go to Previous Page
Go to Next Page